GLP-1 and CGM Convergence Market

GLP-1 and CGM convergence refers to the emerging integration of continuous glucose monitoring technology with GLP-1 receptor agonist therapy management, combining real-time glucose and metabolic data with GLP-1 treatment tracking to provide patients and clinicians with a more comprehensive view of treatment response and metabolic health during weight loss and diabetes management. As GLP-1 therapy has expanded dramatically across both diabetes and weight management populations, device and digital health companies have increasingly explored integrated platforms that combine continuous glucose data with medication tracking and personalized coaching support.

Demand growth through the 2026-2033 window is closely tied to explosive growth in GLP-1 therapy adoption across both diabetic and non-diabetic weight management populations, growing clinical and consumer interest in real-time metabolic data supporting treatment personalization and outcome tracking, and continued digital health platform innovation combining device data with behavioral coaching and treatment adherence support. Expanding integration between CGM device manufacturers and telehealth or digital coaching platforms continues to shape this rapidly emerging convergence category.

The market is valued at USD 650.00 Million in 2026, with device and digital health companies directing substantial investment toward integrated platforms that combine glucose monitoring data with GLP-1 treatment tracking and personalized insights. By 2033, the market is forecast to reach USD 3,659.17 Million, reflecting rapid growth across established diabetic patient applications alongside accelerating adoption among non-diabetic weight management patients.

• The global GLP-1 and CGM convergence market is valued at USD 650.00 Million in 2026 and is projected to reach USD 3,659.17 Million by 2033, expanding at a CAGR of 28.0% across the 2026-2033 forecast period.
• Standalone CGM Devices with GLP-1 Data Integration lead the product-type segment with a 66.0% share in 2026, equivalent to USD 429.00 Million.
• Individuals with Type 2 Diabetes remain the dominant end-user segment, accounting for 58.0% of global demand, or USD 377.00 Million, in 2026.
• North America commands the largest regional share at 61.0% of the global market in 2026.
• Weight management patients without diabetes are emerging as the fastest-growing end-user segment through 2033.

Growth in the GLP-1 and CGM convergence market is driven primarily by explosive growth in GLP-1 therapy adoption, as rapidly expanding GLP-1 prescribing across both diabetes management and weight loss populations creates a growing base of patients for whom integrated metabolic monitoring offers meaningful treatment insight and engagement value.

A second driver is growing clinical and consumer interest in real-time metabolic data, as both prescribers and patients increasingly value continuous glucose data as a tool for understanding treatment response and supporting sustained lifestyle and medication adherence during GLP-1 therapy.

The relative novelty of this convergence category creates limited clinical evidence specifically validating the incremental benefit of combined GLP-1 and CGM data platforms relative to either technology used independently, requiring continued outcomes research to support broader clinical endorsement.

Additionally, reimbursement pathways for continuous glucose monitoring among non-diabetic weight management patients remain limited in many markets, creating a cost barrier that can affect broader adoption of integrated platforms among this rapidly growing patient population.

The expansion of adoption among non-diabetic weight management patients presents a substantial opportunity, as the rapidly growing population using GLP-1 therapy specifically for weight loss, without a diabetes diagnosis, represents a significant and largely untapped market for integrated metabolic monitoring platforms.

A second opportunity lies in continued development of digital coaching and behavioral support platforms that combine device data with personalized guidance, improving treatment adherence and outcomes. Companies that successfully build comprehensive, validated integrated platforms stand to capture significant share as this convergence category matures from an emerging trend toward established clinical practice.

• By Product Type

Standalone CGM Devices with GLP-1 Data Integration lead the product-type segment, accounting for 66.0% of global market value in 2026, equivalent to USD 429.00 Million. Their leadership reflects the established commercial availability and clinical familiarity of continuous glucose monitoring devices now incorporating GLP-1 treatment tracking features. Integrated GLP-1/CGM Digital Platforms represent the fastest-growing product-type category through 2033, driven by growing demand for unified digital health platforms combining device data with comprehensive treatment support.

• By End User

Individuals with Type 2 Diabetes form the leading end-user segment, representing 58.0% of global demand in 2026, or USD 377.00 Million, reflecting this population's established use of both GLP-1 therapy and continuous glucose monitoring as standard diabetes management tools. Weight Management Patients (Non-Diabetic) represent the fastest-growing end-user category, propelled by rapidly expanding GLP-1 use for weight loss among patients without a diabetes diagnosis.

• North America

North America holds the largest regional share, at 61.0% of the global market in 2026, equivalent to USD 396.50 Million. The region's dominance reflects the scale of GLP-1 therapy adoption and well-established continuous glucose monitoring infrastructure across the United States and Canada.

• Europe

Europe accounts for 22.0% of the global market in 2026, valued at USD 143.00 Million. Demand is supported by growing GLP-1 therapy adoption and established diabetes technology infrastructure across major European markets.

• Asia Pacific

Asia Pacific represents 12.0% of the global market in 2026, or USD 78.00 Million. Growth is underpinned by expanding GLP-1 therapy availability and growing diabetes technology adoption across China, Japan, and South Korea.

• Latin America

Latin America contributes 3.0% of the global market in 2026, equivalent to USD 19.50 Million. Growth remains at an early stage, tied to gradual GLP-1 therapy and diabetes technology access expansion in Brazil and Mexico.

• Middle East & Africa

Middle East & Africa holds 2.0% of the global market in 2026, valued at USD 13.00 Million. Growth remains limited, tied to gradual expansion of advanced diabetes technology access across the region.

The global GLP-1 and CGM convergence market is fragmented, with a mix of established continuous glucose monitoring device manufacturers, pharmaceutical companies developing GLP-1 therapies, and digital health platforms building integrated tracking and coaching solutions. Competition centers on device accuracy and integration sophistication, breadth of behavioral coaching and treatment support features, and the ability to build clinical evidence supporting combined platform value. Companies are increasingly differentiating through comprehensive digital platform integration rather than competing on device hardware alone.

Key Market Players

• Dexcom, Inc.
• Abbott Laboratories
• Novo Nordisk A/S
• Eli Lilly and Company
• Medtronic plc
• Senseonics Holdings, Inc.
• Roche Holding AG
• Tandem Diabetes Care, Inc.
• Insulet Corporation
• Signos, Inc.

By Product Type

• Integrated GLP-1/CGM Digital Platforms
• Standalone CGM Devices with GLP-1 Data Integration
• Others

By End User

• Individuals with Type 2 Diabetes
• Weight Management Patients (Non-Diabetic)
• Others

By Distribution Channel

• Direct-to-Consumer/Telehealth
• Clinical/Provider-Prescribed

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa